PMID- 25422588
OWN - NLM
STAT- MEDLINE
DCOM- 20150713
LR  - 20221207
IS  - 1178-1998 (Electronic)
IS  - 1176-9092 (Print)
IS  - 1176-9092 (Linking)
VI  - 9
DP  - 2014
TI  - The durability of sitagliptin in elderly patients with type 2 diabetes.
PG  - 1905-11
LID - 10.2147/CIA.S72396 [doi]
AB  - AIM: To evaluate the durability of sitagliptin and to assess changes in clinical 
      chronic complications following sitagliptin monotherapy for 48 months in elderly 
      patients with type 2 diabetes mellitus (T2DM). SUBJECTS AND METHODS: We enrolled 
      76 drug-naive patients (40 women and 36 men; mean age: 71.3+/-11.7 years) with T2DM 
      who received 25-100 mg of sitagliptin therapy from an outpatient clinic. The 
      observational period for each patient was >48 months, beginning at the time 
      sitagliptin therapy was initiated. The following were measured or performed at 
      the beginning of each year: body mass index; serum total cholesterol, low-density 
      lipoprotein, high-density lipoprotein; triglyceride levels; creatinine (Cr) 
      levels; urine albumin and urine Cr; nonmydriatic fundusgraphy; and semiquantified 
      neuropathy. The fasting plasma glucose and glycated hemoglobin (HbA1c) was 
      measured every 3-6 months. RESULTS: The change in HbA1c was significantly reduced 
      after 6 months of therapy (7.1%+/-0.8% to 6.3%+/-0.2%). No changes in fasting plasma 
      glucose, Cr, serum total cholesterol, triglyceride, low-density lipoprotein, 
      high-density lipoprotein, body mass index, and microvascular complications were 
      apparent. Using repeated measures to test the sequential changes in HbA1c from 
      month 6 to month 48, the test of within-subjects effect was not significant 
      (P=0.34). CONCLUSION: Sitagliptin has a durable effect and stabilizes 
      microvascular complication progression in elderly patients. This study can 
      provide useful data for clinicians and health care professionals using 
      sitagliptin monotherapy in the treatment of elderly patients with T2DM.
FAU - Hsieh, Ching-Jung
AU  - Hsieh CJ
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of 
      Medicine, Kaohsiung, Taiwan.
FAU - Shen, Feng-Chih
AU  - Shen FC
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of 
      Medicine, Kaohsiung, Taiwan.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20141107
PL  - New Zealand
TA  - Clin Interv Aging
JT  - Clinical interventions in aging
JID - 101273480
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Lipids)
RN  - 0 (Pyrazines)
RN  - 0 (Triazoles)
RN  - AYI8EX34EU (Creatinine)
RN  - TS63EW8X6F (Sitagliptin Phosphate)
SB  - IM
MH  - Aged
MH  - Blood Glucose
MH  - Body Mass Index
MH  - Creatinine/blood
MH  - Diabetes Complications/*epidemiology
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Diagnostic Techniques, Ophthalmological
MH  - Female
MH  - Glycated Hemoglobin
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Lipids/blood
MH  - Male
MH  - Middle Aged
MH  - Pyrazines/*therapeutic use
MH  - Sitagliptin Phosphate
MH  - Triazoles/*therapeutic use
MH  - Urinalysis
PMC - PMC4232051
OTO - NOTNLM
OT  - dipeptidyl peptidase IV inhibitor
OT  - oral antidiabetic drugs
OT  - sitagliptin
OT  - type 2 diabetes mellitus
EDAT- 2014/11/26 06:00
MHDA- 2015/07/15 06:00
PMCR- 2014/11/07
CRDT- 2014/11/26 06:00
PHST- 2014/11/26 06:00 [entrez]
PHST- 2014/11/26 06:00 [pubmed]
PHST- 2015/07/15 06:00 [medline]
PHST- 2014/11/07 00:00 [pmc-release]
AID - cia-9-1905 [pii]
AID - 10.2147/CIA.S72396 [doi]
PST - epublish
SO  - Clin Interv Aging. 2014 Nov 7;9:1905-11. doi: 10.2147/CIA.S72396. eCollection 
      2014.